摘要
目的探讨肺表面活性物质联合鼻塞式正压通气(NCPAP)对新生儿呼吸衰竭血清ET-1及CC16的影响。方法选取2017年1月至2018年11月来院就诊患新生儿呼吸衰竭患儿共114例,采用随机数表分组随机分为观察组60例和对照组54例。两组患儿入组后均予对症治疗,对照组患儿予NCPAP,观察组患儿在此基础上加予肺表面活性物质治疗,均连续治疗3 d。比较两组总有效率、治疗前后的血清内皮素-1(ET-1)、Clara细胞蛋白-16(CC16)、血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、动脉血氧饱和度(SaO2)以及不良反应发生率。结果观察组总有效率81.67%(49/60),高于对照组64.81%(35/54),差异有统计学意义(P<0.05)。治疗后,两组患儿血清ET-1、CC16水平均明显降低,且观察组低于对照组(P<0.05)。治疗后两组患儿PaO2、SaO2均明显上升、PaCO2明显下降(P<0.05)。观察组治疗后的PaO2、SaO2高于对照组,PaCO2低于对照组,差异有统计学意义(P<0.05)。观察组和对照组不良反应发生率分别为8.33%(5/60)、9.26%(5/54),差异无统计学意义(P>0.05)。结论新生儿呼吸衰竭采用肺表面活性物质联合NCPAP治疗效果更好,能有效降低血清ET-1及CC16水平。
Objective To investigate the effect of pulmonary surfactant combined with NCPAP on ET-1 and CC16 in neonates with respiratory failure.Methods from January 2017 to November 2018,a total of 117 patients with neonatal respiratory failure were randomly divided into two groups:observation group 60 cases and control group 54 cases.Both groups received routine nursing and symptomatic treatment.The control group was treated with NCPAP to control the symptoms of respiratory failure.The observation group was treated with pulmonary surfactant on this basis.The two groups were treated for 3 consecutive days.The changes of PaO2,PaCO2 and SaO2 levels before and after treatment were compared After treatment,the adverse reactions of the two groups were recorded and counted.The changes of serum ET-1 and CC16 before and after treatment were compared.Results there was no significant difference in PaO2,PaCO2 and SaO2 between the two groups before and after the treatment.The above indexes of the two groups were significantly improved after the treatment,and the patients in the observation group were significantly improved compared with the patients in the control group,the results were statistically significant(P<0.05);the total effective rate of the observation group was 82.46%,the total effective rate of the control group was 64.91%,the effective rate of the observation group was significantly higher than that of the control group,the results were There was statistical significance;there was no significant difference in the incidence of adverse reactions between the two groups;there was no significant difference in the expression of serum ET-1 and CC16 between the two groups before the treatment;after the treatment,the expression of serum ET-1 and CC16 in the two groups were significantly reduced,and the observation group was significantly lower than the control group,the results were statistically significant.Conclusion pulmonary surfactant combined with NCPAP is more effective in the treatment of neonatal respiratory failure,and can effectively reduce the expression of serum ET-1 and CC16.
作者
李俊兰
张晓荣
Li Junlan;Zhang Xiaorong(Department of Pediatrics, 215th Hospital of Shaanxi Nuclear Industry, Xian 712000 China;Department of Pediatrics, Zhuhai People′s Hospital (Zhuhai Hospital affiliated to Jinan University), Zhuhai 519000 China)
出处
《中华肺部疾病杂志（电子版）》
CAS
2020年第5期623-627,共5页
Chinese Journal of Lung Diseases(Electronic Edition)
基金
陕西省社会发展科技攻关项目(2016SF-01987)。
